Nisa Investment Advisors LLC Has $190,000 Stock Holdings in Accolade, Inc. (NASDAQ:ACCD)

Nisa Investment Advisors LLC grew its holdings in Accolade, Inc. (NASDAQ:ACCD - Free Report) by 15,113.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 55,680 shares of the company's stock after purchasing an additional 55,314 shares during the quarter. Nisa Investment Advisors LLC owned about 0.07% of Accolade worth $190,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently made changes to their positions in ACCD. Mission Creek Capital Partners Inc. bought a new stake in shares of Accolade during the third quarter worth $38,000. Pallas Capital Advisors LLC bought a new stake in shares of Accolade during the fourth quarter worth $38,000. IQ EQ FUND MANAGEMENT IRELAND Ltd bought a new stake in shares of Accolade during the third quarter worth $46,000. Wolverine Trading LLC bought a new stake in shares of Accolade during the third quarter worth $51,000. Finally, Point72 Asia Singapore Pte. Ltd. raised its position in shares of Accolade by 1,144.1% during the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 20,913 shares of the company's stock worth $81,000 after acquiring an additional 19,232 shares during the last quarter. Institutional investors own 84.99% of the company's stock.

Accolade Trading Up 0.1 %

NASDAQ:ACCD traded up $0.01 on Friday, reaching $6.89. The company's stock had a trading volume of 1,677,385 shares, compared to its average volume of 3,813,519. Accolade, Inc. has a 1-year low of $3.08 and a 1-year high of $13.93. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.63 and a current ratio of 2.63. The firm has a market cap of $562.16 million, a PE ratio of -3.06 and a beta of 2.08. The business's 50-day moving average price is $4.68 and its two-hundred day moving average price is $4.11.

Accolade (NASDAQ:ACCD - Get Free Report) last posted its earnings results on Friday, January 10th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.31) by $0.01. Accolade had a negative return on equity of 20.74% and a negative net margin of 40.36%. Equities research analysts anticipate that Accolade, Inc. will post -1.2 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ACCD has been the subject of a number of recent research reports. Canaccord Genuity Group restated a "hold" rating on shares of Accolade in a research report on Wednesday, January 8th. Morgan Stanley dropped their price objective on Accolade from $6.00 to $5.00 and set an "equal weight" rating for the company in a report on Tuesday, December 17th. Barclays dropped their price objective on Accolade from $5.50 to $5.00 and set an "equal weight" rating for the company in a report on Wednesday, October 9th. Stifel Nicolaus reiterated a "hold" rating and issued a $7.03 price objective (down previously from $8.00) on shares of Accolade in a report on Thursday, January 9th. Finally, Leerink Partnrs downgraded Accolade from a "strong-buy" rating to a "hold" rating in a report on Wednesday, January 8th. Twelve investment analysts have rated the stock with a hold rating and one has given a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $7.55.

Insider Buying and Selling at Accolade

In other news, CEO Rajeev Singh sold 13,357 shares of the company's stock in a transaction dated Tuesday, December 3rd. The stock was sold at an average price of $3.60, for a total transaction of $48,085.20. Following the completion of the transaction, the chief executive officer now directly owns 814,316 shares of the company's stock, valued at $2,931,537.60. This represents a 1.61 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last ninety days, insiders sold 41,947 shares of company stock valued at $154,439. Company insiders own 8.20% of the company's stock.

About Accolade

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and primary care physicians.